C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019

Publisher Name :
Date: 21-May-2019
No. of pages: 65

C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019

Summary

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Respiratory, Cardiovascular, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)

- The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects

- The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Overview
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development
AstraZeneca Plc
ChemoCentryx Inc
Dompe Farmaceutici SpA
Eli Lilly and Co
Merck & Co Inc
Syntrix Biosystems Inc
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles
AZD-5069 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-5069 + durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2755A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3041658 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CXCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RIST-4721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CCR1 and CXCR2 for Solid and Hematological tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Dormant Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2019: Researchers report SX-682 could enhance multiple forms of T cell-based immunotherapies in solid tumors
Mar 26, 2019: New study points to SX-682 as strategy to boost immunotherapy effectiveness in advanced colorectal cancer
Feb 04, 2019: Syntrix wins $3.4M NIH grant to conduct phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
Apr 26, 2017: Trial investigates use of asthma drug for patients with heart conditions
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin
Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AstraZeneca Plc, H1 2019
Pipeline by ChemoCentryx Inc, H1 2019
Pipeline by Dompe Farmaceutici SpA, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by Merck & Co Inc, H1 2019
Pipeline by Syntrix Biosystems Inc, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
  • Global Dental Silica Market Professional Survey 2019 by Manufacturers, Regions, Countries, Types and Applications, Forecast to 2024
    Published: 19-Jul-2019        Price: US 2900 Onwards        Pages: 193
    The Dental Silica market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for Dental Silica. Global Dental Silica industry market professional research 2014-2024, is a report which provides the details about industry overview, industry chain, market size (sales, revenue, and g......
  • Global Eye Allergy Therapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Jul-2019        Price: US 3480 Onwards        Pages: 118
    All types of eye allergies are associated with chronic symptoms such as ocular itching inflammation redness and watery eyes, which are persistently disturbing, having an adverse effect on patients' life. Scope of the Report: The worldwide market for Eye Allergy Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focu......
  • Global Radiodermatitis Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Jul-2019        Price: US 3480 Onwards        Pages: 119
    Radiodermatitis is the integumentary system's response to exposure to ionizing radiation. Scope of the Report: The worldwide market for Radiodermatitis Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Radiodermatitis Treatment in global market, especially in North America, Europe and Asia-Pacific, Sou......
  • Global Staphylococcal Infection Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Jul-2019        Price: US 3480 Onwards        Pages: 124
    Staphylococcal infections are usually caused by the organism Staphylococcus aureus. Scope of the Report: The worldwide market for Staphylococcal Infection Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Staphylococcal Infection Drugs in global market, especially in North America, Europe and Asia-Pacific, ......
  • Global Equine Supplement Products Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Jul-2019        Price: US 3480 Onwards        Pages: 124
    Equine supplement products market is driven by rise in demand for herbal equine supplements, increase in incidence of equine diseases, and surge in government initiatives toward equine health. Scope of the Report: The worldwide market for Equine Supplement Products is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on th......
  • Global Postoperative Pain Therapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 19-Jul-2019        Price: US 3480 Onwards        Pages: 120
    As the global healthcare space is seeing a palpable shift toward a 'value-based care' model, postoperative pain management is gaining its very own eminence. Scope of the Report: The worldwide market for Postoperative Pain Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Postoperative Pain Therapeuti......
  • 2019-2023 Global Thrombin Time Market: US, Europe, Japan--Volume and Sales Segmentation Forecasts, Competitive Landscape, Current Methods and Instrumentation, Opportunities for Suppliers
    Published: 18-Jul-2019        Price: US 3450 Onwards        Pages: 196
    The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next five years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and Thrombin Time testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction......
  • Benzyl trimethyl ammonium bromide (CAS 56-93-9) Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 18-Jul-2019        Price: US 3000 Onwards        Pages: 143
    Benzyl trimethyl ammonium bromide Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Benzyl trimethyl ammonium bromide industry with a focus on the Chinese market. The report provides key statistics on the market status of the Benzyl trimethyl ammonium bromide manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insi......
  • Benzyl triethyl ammonium bromide (CAS 56-37-1) Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 18-Jul-2019        Price: US 3000 Onwards        Pages: 148
    Benzyl triethyl ammonium bromide Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Benzyl triethyl ammonium bromide industry with a focus on the Chinese market. The report provides key statistics on the market status of the Benzyl triethyl ammonium bromide manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs